重组活化凝血因子VII与新生儿心脏术后血栓形成相关
该回顾性研究分析9年间414例新生儿416次体外循环心脏手术,发现31%手术使用rVIIa,使用rVIIa者血栓发生率22%(28/129),未用者6%(17/287),校正后OR 3.5(95%CI 1.7-6.9,P=0.0004);Norwood术后血栓者ECMO支持率和死亡率更高。
要点
- 新生儿体外循环心脏手术中rVIIa使用与血栓形成独立相关(校正OR 3.5)。
- 使用rVIIa的手术血栓发生率为22%,未使用者为6%。
- Norwood术后发生血栓者ECMO支持率和死亡率更高。
核心结论
- 新生儿体外循环心脏手术中,使用rVIIa与血管内血栓形成增加相关。
- Norwood术后发生血栓者死亡率更高。
研究设计与样本
- 回顾性研究,9年间414例新生儿共416次体外循环心脏手术。
主要发现
- 总体血栓频率45/416(11%)。
- 未用rVIIa者血栓17/287(6%),使用rVIIa者血栓28/129(22%)。
- rVIIa与血栓形成相关(OR 4.4,95%CI 2.3-8.4;P<0.0001)。
- 校正PIM2评分、RACHS和ECMO使用后,rVIIa与血栓形成强相关(OR 3.5,95%CI 1.7-6.9;P=0.0004)。
- 血栓患者住院时间延长;Norwood术后使用rVIIa并发生血栓者ECMO支持率和死亡率更高。
临床怎么用
- 新生儿体外循环心脏术后使用rVIIa需权衡血栓风险,尤其Norwood术后。
- 使用rVIIa后应加强血栓监测。
局限性
- 回顾性研究设计。
- RACHS-1分类和PIM2评分对血栓形成无影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study is to determine whether recombinant activated factor VII (rVIIa) was associated with thrombus formation in neonates undergoing cardiac surgery. METHODS: This is a retrospective study of neonates undergoing surgical repair of congenital cardiac lesions during a 9-year period. RESULTS: In our study, 416 cardiac operations requiring cardiopulmonary bypass (CPB) were performed on 414 neonates. The overall intravascular thrombus (thrombus) frequency for all operations was 45 of 416 (11%). A thrombus developed in 17 of 287 (6%) operations when rVIIa was not given. rVIIa was administered in 129 of 416 (31%) operations. Thrombus formation occurred in 28 of 129 (22%) operations when rVIIa was administered. There was an association between rVIIa use and thrombus formation [odds ratio (OR) 4.4, 95% confidence interval (CI) 2.3-8.4; P < 0.0001]. Patients with thrombus formation had an increased length of stay compared to those without thrombus. Neonates who underwent the Norwood procedures and received rVIIa and developed thrombus were more likely to be supported with extracorporeal membrane oxygenation (ECMO) and had a higher mortality compared to Norwood patients without thrombus. Logistic analysis adjusted for the paediatric index of mortality 2 score, the risk adjustment for congenital heart surgery and the use of ECMO demonstrated a strong association between rVIIa administration and thrombus formation (OR 3.5, 95% CI 1.7-6.9; P = 0.0004). However, there was no effect of the risk adjustment for congenital heart surgery-1 category or the paediatric index of mortality 2 score on thrombus formation. CONCLUSIONS: In neonates who underwent CPB surgery, administration of rVIIa was associated with an increased occurrence of intravascular thrombus formation compared to neonates not given rVIIa. In the Norwood population, thrombus formation was associated with a higher mortality.
引用
- Christoff AS, Winlaw DS, Curtin J, et al. Recombinant activated factor VII in neonatal cardiac surgery. Eur J Cardiothorac Surg. 2019. PMID: 30715304. doi:10.1093/ejcts/ezy483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。